SLP vs. MDRX, NRC, MDXG, TYRA, CNTA, MGNX, EYPT, ABVX, RLAY, and INVA
Should you be buying Simulations Plus stock or one of its competitors? The main competitors of Simulations Plus include Veradigm (MDRX), National Research (NRC), MiMedx Group (MDXG), Tyra Biosciences (TYRA), Centessa Pharmaceuticals (CNTA), MacroGenics (MGNX), EyePoint Pharmaceuticals (EYPT), ABIVAX Société Anonyme (ABVX), Relay Therapeutics (RLAY), and Innoviva (INVA).
Veradigm (NASDAQ:MDRX) and Simulations Plus (NASDAQ:SLP) are both small-cap business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.
Veradigm received 356 more outperform votes than Simulations Plus when rated by MarketBeat users. However, 62.82% of users gave Simulations Plus an outperform vote while only 60.33% of users gave Veradigm an outperform vote.
Simulations Plus has a net margin of 16.22% compared to Simulations Plus' net margin of 0.00%. Veradigm's return on equity of 7.95% beat Simulations Plus' return on equity.
Veradigm has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Simulations Plus has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
78.1% of Simulations Plus shares are held by institutional investors. 2.3% of Veradigm shares are held by company insiders. Comparatively, 20.9% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Veradigm had 1 more articles in the media than Simulations Plus. MarketBeat recorded 4 mentions for Veradigm and 3 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.46 beat Veradigm's score of 0.15 indicating that Veradigm is being referred to more favorably in the media.
Veradigm has higher revenue and earnings than Simulations Plus.
Veradigm currently has a consensus price target of $11.25, suggesting a potential upside of 46.10%. Simulations Plus has a consensus price target of $53.00, suggesting a potential upside of 13.49%. Given Simulations Plus' higher possible upside, analysts plainly believe Veradigm is more favorable than Simulations Plus.
Summary
Simulations Plus beats Veradigm on 10 of the 16 factors compared between the two stocks.
Get Simulations Plus News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Simulations Plus Competitors List
Related Companies and Tools
